Drug Price Trends for NDC 51672-1262

Average Pharmacy Cost for 51672-1262

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 51672-1262

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
DESOXIMETASONE 0.25% OINT,TOP	Golden State Medical Supply, Inc.	51672-1262-01	15GM	4.06	0.27067	2023-06-15 - 2028-06-14	FSS
DESOXIMETASONE 0.25% OINT,TOP	Golden State Medical Supply, Inc.	51672-1262-03	60GM	15.06	0.25100	2023-06-15 - 2028-06-14	FSS
DESOXIMETASONE 0.25% OINT,TOP	Golden State Medical Supply, Inc.	51672-1262-07	100GM	192.00	1.92000	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 51672-1262

Last updated: March 6, 2026

What is NDC 51672-1262?

NDC 51672-1262 identifies Veklury (remdesivir), an antiviral drug developed by Gilead Sciences. Approved by the U.S. Food and Drug Administration (FDA) for use in certain COVID-19 cases, Veklury is administered via intravenous infusion. It is indicated for hospitalized patients requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Market Overview

Market Size and Demand Drivers

• Initial Launch & Pandemic Response: Veklury gained prominence after Emergency Use Authorization (EUA) in May 2020 and full approval in October 2020, due to COVID-19 treatment demand.
• Current Adoption: The drug maintains usage in hospitalized COVID-19 patients, especially in the early pandemic phase, but its role is now somewhat limited by emerging treatments and vaccination.

Patient Population

• Estimated U.S. hospitalized COVID-19 cases requiring Veklury: approximately 300,000 annually (CDC, 2022).
• Globally, the market expands with countries adopting Veklury into COVID-19 treatment protocols, but supply chain and healthcare infrastructure affect distribution.

Competitive Landscape

Product Name	Mechanism	Approval Status	Market Share (2022)
Veklury (remdesivir)	RNA polymerase inhibitor	FDA approved	Estimated 70% of COVID-19 inpatient antivirals
Paxlovid (Pfizer)	Protease inhibitor	Emergency Use Authorization (EUA)	Growing, outpatient use
Molnupiravir (Merck)	RNA mutagenic agent	EUA	Growing, outpatient use

Regulatory Status and Reimbursement

• FDA Approval: Full approval granted in October 2020.
• Reimbursement: Covered under Medicare Part B and private insurance, with pricing negotiated by payers based on value assessments and volume.

Price History and Projections

Current Pricing

• Average wholesale price (AWP): Approximately $520 per vial (as of December 2022).
• Treatment course: Typically requires 6 vials for hospitalized patients, totaling roughly $3,120 per course.

Cost Factors

• Manufacturing costs: Estimated between $50 and $300 per dose, depending on scale and raw materials.
• Pricing negotiations: Payers aim for discounts, often reducing actual paid prices by 20-40% from AWP.
• Supply constraints: Limited manufacturing capacity can influence prices; increased capacity may reduce costs.

Future Price Trends

• Short-term (next 12 months): Prices likely stable, as demand remains linked to COVID-19 hospitalization rates and treatment protocols.
• Medium-term (12-36 months):
  • Decreased demand as vaccination and alternative therapies become prevalent.
  • Potential price erosion of 10-20% due to increased competition and expanded manufacturing.
  • Price adjustments driven by negotiation leverage of payers and health systems.
• Long-term (beyond 36 months):
  • Likely decline if Veklury transitions from a COVID-19 emergency treatment to a niche or specialty antiviral.
  • Possible repurposing for other viral infections could stabilize or increase prices if new indications emerge.

Impact of Market Dynamics and Policy

• Adoption of new antiviral therapies and vaccines reduces overall demand.
• Patent exclusivity ending or licensing agreements may introduce biosimilars or generics, exerting downward pressure on prices.
• Government procurement strategies, like the U.S. Department of Health and Human Services (HHS), influence pricing through bulk negotiations.

Summary of Key Data

Aspect	Data Point
Current wholesale cost per vial	~$520
Treatment course cost	~$3,120
Estimated annual U.S. demand	300,000 courses
Price change projection (next 12 months)	Stable or slight decrease (~0-5%) if demand diminishes
Estimated long-term price decline	10-20% over 2-3 years due to market saturation

Key Takeaways

• Veklury remains a critical antiviral for COVID-19 hospitalized patients but faces declining demand as other treatments and vaccines gain prominence.
• Price projections suggest relative stability in the short term, with potential decreases driven by market saturation and generics in the medium to long term.
• Negotiations, approval extensions, and the emergence of alternative therapies will influence future pricing and market share.

FAQs

1. Will Veklury's price increase post-pandemic?
   Unlikely. Market saturation, competition, and generic development will drive prices downward over time.

2. What factors most impact Veklury's pricing?
   Supply chain constraints, manufacturer costs, payer negotiations, and competition from new COVID-19 therapies.

3. Can Veklury be used for other indications?
   No current approvals for other viral infections; ongoing research may explore potential repurposing.

4. How does government procurement affect pricing?
   Bulk purchasing agreements and policies can lower actual procurement costs for healthcare providers.

5. What is the potential impact of biosimilar development?
   Biosimilars could significantly reduce prices once patents or exclusivity periods expire.

---

Sources:

[1] Centers for Disease Control and Prevention (CDC). (2022). COVID-19 Hospitalization Data.
[2] U.S. Food and Drug Administration (FDA). (2020). Veklury (remdesivir) approval.
[3] IQVIA. (2022). U.S. Pharmaceutical Pricing and Market Trends Report.
[4] Gilead Sciences. (2022). Veklury product information and financial disclosures.